revumenib
Jump to navigation
Jump to search
Indications
- relapsed or refractory KMT2A-rearranged or NPM1-mutant acute leukemia
Mechanism of action
- menin inhibitor
More general terms
References
- ↑ Brooks M Novel Drug Leads to 'Impressive' Responses in Advanced Leukemia. Medscape. March 20, 2023 https://www.medscape.com/viewarticle/989871